Opus Genetics, Inc. officer George Magrath filed a Form 144 notice on November 3, 2026, proposing to sell 28,258 shares of common stock on NASDAQ to cover tax liability arising from an RSU vest.

Key Highlights

  • Proposed sale: 28,258 shares of Opus Genetics common stock with an aggregate market value of $110,183.59, according to the filing.
  • Seller: George Magrath, identified as an officer of Opus Genetics, Inc.
  • Source of shares: 100,000 shares acquired on November 1, 2026 via RSU grant vest from the issuer, with cash payment on November 3, 2026.
  • Approximate sale date: November 3, 2026, through broker Raymond James and Associates, Inc., on NASDAQ.
  • Prior sales: Magrath sold 9,591 shares of common stock on October 23, 2026, for gross proceeds of $34,384.00, as reported in the filing.
  • Non-discretionary trade: The filing states, "Trade is not discretionary as sale is required to cover any tax liability."
  • Shares outstanding: 83,195,823 shares of common stock outstanding at the time of filing.

George Magrath's Rule 144 Notice: RSU Vest and Tax-Cover Sale at Opus Genetics

Opus Genetics, Inc., headquartered at 8 Davis Drive, Suite 220, Durham, North Carolina, is the issuer named in this Form 144 notice filed with the U.S. Securities and Exchange Commission on November 3, 2026. The filing was submitted by Rashida Mitchell as duly authorized representative of Raymond James and Associates, Inc., acting as attorney-in-fact for George N Magrath. The company's securities trade on NASDAQ, and the SEC file number listed is 001-34079.

According to the filing, Magrath acquired 100,000 shares of common stock on November 1, 2026, through an RSU grant vest from the issuer, with cash payment dated November 3, 2026. Of those shares, 28,258 are proposed for sale at an aggregate market value of $110,183.59, with Raymond James and Associates, Inc. named as the executing broker. The filing explicitly notes the trade is non-discretionary: "sale is required to cover any tax liability."

The filing also discloses that Magrath sold 9,591 shares of Opus Genetics common stock on October 23, 2026, generating gross proceeds of $34,384.00. This prior sale is included as required disclosure of securities sold during the past three months by the person for whose account the proposed securities are to be sold. Total shares of common stock outstanding at the time of the notice are reported as 83,195,823.

What Was Disclosed

Opus Genetics officer George Magrath filed a Form 144 notice proposing to sell 28,258 shares of common stock, valued at $110,183.59, on NASDAQ on November 3, 2026, to cover tax obligations following a 100,000-share RSU vest on November 1, 2026.